OncoDaily on Horizon: "Improved Overall Survival with Gotistobart Versus Docetaxel in Squamous NSCLC – "

No JavaScript? That's cool, but you'll need to disable Turbo mode as it uses JavaScript in the client.

OncoDaily @oncodaily

Improved Overall Survival with Gotistobart Versus Docetaxel in Squamous NSCLC – ESMO - European Society for Medical Oncology @myESMO oncodaily.com/voices/nsclc-4… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

8:30 AM · Mar 28, 2026 · 44 Views

1 Likes

1

44